Select a patient below to see how GLIVEC extends survival in patients with KIT+ GIST

Meet Hanna

Recently
Resected
Patient

Meet Karen

Adjuvant
Patient

Meet Chen

Newly
Metastatic
Patient

Meet Omar

Metastatic
Patient With
Progression

Models are used for illustrative purposes only throughout the site. Patient quotes are intended for guidance only and do not reflect actual patient testimonials.

In KIT+ GIST, GLIVEC is a key partner in the patient journey

Historically, GIST was a poorly characterized disease entity, frequently misdiagnosed as smooth muscle tumour.Research advances and implementation of new technologies have transformed our knowledge of GIST in terms of cellular and molecular etiology, diagnostic strategies, and treatment options.2

References: 1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83. 2. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459-465.